Outcomes of Heart Failure in COVID-19 Patients: An Appalachian Experience

Background The Southeastern rural areas of the USA have a higher prevalence of heart failure (HF). Coronavirus disease 2019 (COVID-19) infection is associated with poor outcomes in patients with HF. Our study aimed to compare the outcomes of hospitalized HF patients with and without COVID-19 infection specifically in rural parts of the USA. Methods We conducted a retrospective cohort study of HF patients with and without COVID-19 hospitalized in Southeastern rural parts of the USA by using the Appalachian Regional Healthcare System. Analyses were stratified by waves from April 1, 2020 to May 31, 2021, and from June 1, 2021 to October 19, 2021. Results Of the 14,379 patients hospitalized with HF, 6% had concomitant COVID-19 infection. We found that HF patients with COVID-19 had higher mortality rate compared to those without COVID-19 (21.8% versus 3.8%, respectively, P < 0.01). Additionally, hospital resource utilization was significantly higher in HF patients with COVID-19 compared to HF patients without COVID-19 with intensive care unit (ICU) utilization of 21.6% versus 13.8%, P < 0.01, mechanical ventilation use of 17.3% versus 6.2%, P < 0.01, and vasopressor/inotrope use of 16.8% versus 7.9%, P < 0.01. A lower percentage of those with COVID-19 were discharged home compared to those without a COVID-19 diagnosis (63.4% versus 72.0%, respectively). There was a six-fold greater odds of dying in the first wave and seven-fold greater odds of dying in the second wave. Conclusions Our study confirms previous findings of poor outcome in HF patients with COVID-19. There is a need for review of healthcare resources in rural hospitals which already face numerous healthcare challenges.

[1]  Lauren Shaw,et al.  Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–January 31, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  Jennifer Abbasí The COVID Heart-One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks. , 2022, JAMA.

[3]  L. Wisnieski,et al.  Predictors of Mortality for Patients with COVID-19 in the Rural Appalachian Region , 2022, International journal of general medicine.

[4]  Vinayak Mishra,et al.  COVID-19 Infection and Late Manifestation of Pulmonary Aspergillosis , 2022, Journal of investigative medicine high impact case reports.

[5]  Kai Chen,et al.  Renin–Angiotensin System Blocker in COVID-19. A Single Center Study. , 2021, Journal of cardiovascular pharmacology.

[6]  K. Kong,et al.  Association Between Cardiovascular Risk Factors and the Severity of Coronavirus Disease 2019: Nationwide Epidemiological Study in Korea , 2021, Frontiers in Cardiovascular Medicine.

[7]  E. Zell,et al.  Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–April 10, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[8]  A. Marcus,et al.  Model of End-Stage Liver Disease (MELD) Score as a Predictor of In-Hospital Mortality in Patients with COVID-19: A Novel Approach to a Classic Scoring System , 2021, Cureus.

[9]  A. Volgman,et al.  Impact of pre-existing heart failure on 60-day outcomes in patients hospitalized with COVID-19 , 2021, American Heart Journal Plus: Cardiology Research and Practice.

[10]  S. Cutter,et al.  Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis of South Carolina , 2021, PloS one.

[11]  B. Dautzenberg,et al.  Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study , 2021, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[12]  S. Solomon,et al.  Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19 , 2020, JACC: Heart Failure.

[13]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, New England Journal of Medicine.

[14]  K. Dziadkowiec,et al.  The Effect of Hydroxychloroquine on In-Hospital Mortality in COVID-19. , 2020, HCA healthcare journal of medicine.

[15]  Saleema A. Karim,et al.  Deaths From COVID-19 in Rural, Micropolitan, and Metropolitan Areas: A County-Level Comparison. , 2020, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[16]  N. Dewaswala,et al.  Does Thrombocytopenia Truly Correlate with COVID-19 Severity? , 2020, Blood.

[17]  J. Cheung,et al.  Troponin and Other Biomarker Levels and Outcomes Among Patients Hospitalized With COVID‐19: Derivation and Validation of the HA2T2 COVID‐19 Mortality Risk Score , 2020, Journal of the American Heart Association.

[18]  K. Dziadkowiec,et al.  Cardiac Troponin-I and COVID-19: A Prognostic Tool for In-Hospital Mortality , 2020, Cardiology research.

[19]  C. Plymen,et al.  The effect of concomitant COVID‐19 infection on outcomes in patients hospitalized with heart failure , 2020, ESC heart failure.

[20]  Kapil Gupta,et al.  S1021 MELD-Na Score Prognostic Utility and Implementation in Clinically Relevant Outcomes of Patients With SARS-CoV-2 , 2020 .

[21]  Kai Chen,et al.  HIGH INCIDENCE OF SPONTANEOUS PNEUMOTHORAX IN CRITICALLY ILL PATIENTS WITH SARS-COV-2 , 2020, Chest.

[22]  Kapil Gupta,et al.  S1133 MELD, MELD-Na, and MELD-Albumin Scores as Predictors of Mortality in Patients With SARS-CoV-2: An Uncanny Relationship During Troubling Times , 2020 .

[23]  Kai Chen,et al.  VALIDATION OF SOFA SCORE IN CRITICALLY ILL PATIENTS WITH COVID-19 , 2020, Chest.

[24]  K. Gupta,et al.  S1132 MELD Score as a Predictor of Mortality in Patients With SARS-CoV-2: A New Application for a Classic Scoring System , 2020, American Journal of Gastroenterology.

[25]  M. Banerjee,et al.  Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review , 2020, SN Comprehensive Clinical Medicine.

[26]  I. Pavord,et al.  Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people , 2020, Heart.

[27]  M. Cameli,et al.  COVID-19 in patients with heart failure: the new and the old epidemic , 2020, Postgraduate Medical Journal.

[28]  R. Starling,et al.  Heart failure and COVID-19 , 2020, Heart Failure Reviews.

[29]  Andrew J. Sauer,et al.  Impact of congestive heart failure and role of cardiac biomarkers in COVID-19 patients: A systematic review and meta-analysis , 2020, Indian Heart Journal.

[30]  N. Reza,et al.  Considerations for Heart Failure Care During the COVID-19 Pandemic , 2020, JACC: Heart Failure.

[31]  S. Solomon,et al.  COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease , 2020, European journal of heart failure.

[32]  C. Rojas-Moreno,et al.  Treating COVID‐19 in Rural America , 2020, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[33]  C. SelvaaKumar,et al.  A computational insight of the improved nicotine binding with ACE2-SARS-CoV-2 complex with its clinical impact , 2020, 2004.14943.

[34]  Aaron van Dorn,et al.  COVID-19 exacerbating inequalities in the US , 2020, The Lancet.

[35]  Jacques Cornuz,et al.  COVID-19 and Smoking , 2020, Archives des Maladies du Coeur et des Vaisseaux - Pratique.

[36]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[37]  Manish Bansal,et al.  Cardiovascular disease and COVID-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[38]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[39]  F. Ruschitzka,et al.  COVID-19 Illness and Heart Failure , 2020, JACC: Heart Failure.

[40]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[41]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[42]  Wei Liu,et al.  Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province , 2020, Chinese medical journal.

[43]  P. Eke,et al.  Health-Related Behaviors by Urban-Rural County Classification — United States, 2013 , 2017, Morbidity and mortality weekly report. Surveillance summaries.

[44]  Ali Ahmed,et al.  Evidence of a "heart failure belt" in the southeastern United States. , 2011, The American journal of cardiology.

[45]  T. Greenough,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[46]  C. Heneghan The Centre for Evidence-Based Medicine 9th UK workshop , 2004 .

[47]  D. Gentry Daniel Gentry, PhD, Clinical Professor and Program Director, University of Iowa College of Public Health. , 2018, Journal of healthcare management / American College of Healthcare Executives.